Author:
Watanabe Naoki,Nagata Tetsuya,Satou Youhei,Masuda Satoru,Saito Takashi,Kitagawa Hidetoshi,Komaki Hirofumi,Takagaki Kazuchika,Takeda Shin’ichi
Funder
Grants-in-Aid for Research on Nervous and Mental Disorders
Health and Labour Sciences Research Grants for Translation Research
Comprehensive Research on Disability Health and Welfare
Ministry of Health, Labour and Welfare of Japan
Grants for Promoting Clinical Trials for the Development of New Drugs and Medical Devices
Health and Labour Science Research Grants for Comprehensive Research on Persons with Disabilities
Japan Agency for Medical Research and Development
Takeda Science Foundation
Subject
Drug Discovery,Molecular Medicine
Reference25 articles.
1. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy;Mah;Neuromuscul. Disord.,2014
2. The muscular dystrophies;Emery;Lancet,2002
3. Therapeutic advances in muscular dystrophy;Leung;Ann. Neurol.,2013
4. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy;Mendell;Ann. Neurol.,2016
5. Sarepta Therapeutics (2015). Sarepta Therapeutics announces FDA has filed eteplirsen NDA for the potential treatment of Duchenne muscular dystrophy for patients amenable to exon 51 skipping. http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-has-filed-eteplirsen-nda.
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献